|
Fig. 6 Recombinant zTumstain, the NC1 domain of the α3 chain of type IV collagen, shows conserved antiangiogenic activity on human endothelial cells. (A) Schematic depiction of Col4 α3α4α5 protomer and cleavage site releasing Tumstatin (α3 NC1 domain). (B) Relative HUVECs proliferation when treated with the indicated concentration of eukaryotically produced zTumstatin, n = 3 wells per condition. Positive control: 10% FBS, Negative control: 0.1% FBS. (C) HUVECs migration in a Boyden-chamber assay, n = 4–6 wells per condition. (D) Representative macroscopic image of control and zTumstatin Matrigel plug (encircled) and blood vessels (arrows). (E) Representative H&E section of control and zTumstatin Matrigel plug (black arrows point to blood vessels) and quantification of averaged blood vessels per 200× field per plug, n = 8 plugs per group (two plug per mouse and four mice per group). (B,C) One-way ANOVA, (E) unpaired two-tailed t test, ns: not significant, **p < 0.01, ***p < 0.001, and ****p < 0.0001.